right here, we explain how this programme led to the invention and continuing development of Glivec (Gleevec in The us), the primary selective tyrosine-kinase inhibitor to become authorised for that treatment of the cancer. Imatinib use may cause lightening/depigmentation or darkening/repigmentation of hair (as is the case with some other tyrosine